2018 Alzheimer’s Disease Research Summit

This program completed in June 2018.

The National Institutes of Health (NIH) convened the 3rd Alzheimer’s Disease (AD) Research Summit held on March 1-2, 2018 in Bethesda, Maryland. The program built on the foundation laid by the 2012 and 2015 NIH AD Research Summits and the U.S. National Alzheimer’s Project Act (NAPA)/National Plan to Address AD.

The Summit’s central goal was to continue the development of an integrated multidisciplinary research agenda necessary to address critical knowledge gaps and accelerate the discovery and delivery of efficacious treatments for AD patients at all stages of disease. Key to achieving this goal was the identification of resources, infrastructure and multi-stakeholder partnerships necessary to successfully implement this research agenda and strategies to empower patients and engage citizens.

The event brought together leading researchers, innovators and public advocates from academia, industry, the not-for-profit sector and NIH. The program featured progress made toward achieving the National Plan’s research goal to Treat and Prevent Alzheimer’s by 2025, as well as a robust discussion on the continued transformation of the process of AD research and drug development into one that is participatory, collaborative, well-integrated and capable of delivering the cures that are so desperately needed.

 

Goals

  • Measure the progress made towards achieving the National Plan’s research goal to Treat and Prevent Alzheimer’s Disease by 2025.
  • Continue the development of an integrated multidisciplinary research agenda necessary to address critical knowledge gaps and accelerate the discovery and delivery of efficacious treatments for AD patients at all stages of disease.
  • Identify resources, infrastructure and multi-stakeholder partnerships necessary to successfully implement this research agenda and strategies to empower patients and engage citizens.

Results & Accomplishments

The 2018 Summit convened more than 80 leading experts on Alzheimer's Disease and other complex diseases, who developed over 50 recommendations that will serve as a framework for future Alzheimer's disease research.

Partners

Public-Sector Partners:
National Institute on Aging (NIA)*

Private-Sector Partners:
Accelerate Cure/Treatments for Alzheimer’s Disease (ACT-AD)*
Alzheimer’s Association*
Alzheimer's Drug Discovery Foundation*
Biogen*
Genentech*
GHR Foundation*
The Rosalinde and Arthur Gilbert Foundation*
Merck & Co., Inc., Kenilworth, New Jersey, U.S.A.*
The Shiley Foundaton*
UsAgainstAlzheimer’s*

FNIH Contacts

Development office at development@fnih.org.